Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes

被引:4
作者
Chang-Claude, J
Becher, H
Caligo, M
Eccles, D
Evans, G
Haites, N
Hodgson, S
Moller, P
Weber, BHF
Stoppa-Lyonnet, D
机构
[1] Deutsch Krebsforschungszentrum, Div Epidemiol, D-69120 Heidelberg, Germany
[2] Univ Pisa, Dept Oncol, I-56126 Pisa, Italy
[3] Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England
[4] St Marys Hosp, Clin Genet Serv, Manchester M13 0JH, Lancs, England
[5] Univ Aberdeen, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland
[6] Guys Hosp, Genet Ctr, London SE1 9RT, England
[7] Norwegian Radium Hosp, Unit Med Genet, N-0310 Oslo, Norway
[8] Inst Human Genet, D-97074 Wurzburg, Germany
[9] Inst Curie, Serv Genet Oncol, F-75231 Paris, France
关键词
genetic counselling; genetic risk assessment; familial breast cancer;
D O I
10.1155/1999/238375
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
For genetic counselling of a woman on familial breast cancer, an accurate evaluation of the probability that she carries a germ-line mutation is needed to assist:in making decisions about genetic-testing. We used data from eight collaborating centres comprising 618 families (346 breast cancer only, 239 breast or ovarian cancer) recruited as research families or counselled for familial breast cancer, representing a broad range of family structures. Screening was performed in affected women from 618 families for germ-line mutations in BRCA1 and in 176 families for BRCA2 mutations, using different methods including SSCP, CSGE, DGGE, FAMA and PTT analysis followed by direct sequencing. Germ-line BRCA1 mutations were detected in 132 families and BRCA2 mutations in 16 families. The probability of being a carrier of a dominant breast cancer gene was calculated for the screened individual under me established genetic model for breast cancer susceptibility, first, with parameters for age-specific penetrances for breast cancer only [7] and, second, with age-specific penetrances for ovarian cancer in addition [20]. Our results indicate that the estimated probability of carrying a dominant breast cancer gene gives a direct measure of the likelihood of detecting mutations in BRCA1 and BRCA2. For breast/ovarian cancer families, the genetic model according to Narod et al. [20] is preferable for calculating the proband's genetic risk, and gives detection rates that indicate a 50% sensitivity of the gene test. Due to the incomplete BRCA2 screening of the families, we cannot yet draw any conclusions with respect to the breast cancer only families.
引用
收藏
页码:53 / 65
页数:13
相关论文
共 30 条
[1]  
Anderson TI, 1996, AM J HUM GENET, V59, P486
[2]  
Berman DB, 1996, CANCER RES, V56, P3409
[3]   Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes [J].
Chang-Claude, J ;
Dong, J ;
Schmidt, S ;
Shayeghi, M ;
Komitowski, D ;
Becher, H ;
Stratton, MR ;
Royer-Pokora, B .
JOURNAL OF MEDICAL GENETICS, 1998, 35 (02) :116-121
[4]  
CLAUS EB, 1991, AM J HUM GENET, V48, P232
[5]  
CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO
[6]  
2-5
[7]   Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations [J].
Durocher, F ;
ShattuckEidens, D ;
McClure, M ;
Labrie, F ;
Skolnick, MH ;
Goldgar, DE ;
Simard, J .
HUMAN MOLECULAR GENETICS, 1996, 5 (06) :835-842
[8]   Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13 [J].
Easton, DF ;
Steele, L ;
Fields, P ;
Ormiston, W ;
Averill, D ;
Daly, PA ;
McManus, R ;
Neuhausen, SL ;
Ford, D ;
Wooster, R ;
CannonAlbright, LA ;
Stratton, MR ;
Goldgar, DE .
AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (01) :120-128
[9]  
EASTON DF, 1995, AM J HUM GENET, V56, P265
[10]  
EASTON DF, 1993, AM J HUM GENET, V52, P678